H.C. Wainwright upgraded Akebia Therapeutics to Buy from Neutral with a $3.75 price target. With meeting minutes confirmation, the analyst is now :highly confident” in the FDA approval of vadadustat early next year. The firm expects vadadustat’s FDA approval in March 2024, saying the meeting minutes “fully aligned” with an expedited approval path.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKBA:
- Akebia reaffirms 2023 Auryxia net product revenue guidance of $175M-$180M
- Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Akebia reports Q2 EPS (6c) vs. 15c last year
- Options Volatility and Implied Earnings Moves Today, August 25, 2023
- Notable companies reporting before tomorrow’s open
